Today's pre-market stock movers: PLTR, BBBY, BNTX, GOLD and more

• $Karuna Therapeutics(KRTX.US)$ +42.6% (also reports topline results from its Phase3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT), $monday.com(MNDY.US)$ +15.1%, $W&T Offshore(WTI.US)$ +6.7%, $HF Sinclair(DINO.US)$ +5.3%, $Viatris(VTRS.US)$ +4.3%, $Kosmos Energy(KOS.US)$ + 3.2%, $Holly Energy(HEP.US)$ +3.2%, $Barrick Gold(GOLD.US)$ +2.9%, $Treehouse Foods(THS.US)$ +0.7%, $Berkshire Hathaway-B(BRK.B.US)$+0.5%

• $Magic Empire Global(MEGL.US)$ +112%(continued volatility)

• $Bed Bath & Beyond Inc(BBBY.US)$ +39.3% (early volatility; high short interest)

• $Kodiak Sciences(KOD.US)$ +37.1% (reports positive topline results from BEACON Phase 3 Study of tarcocimab tedromer(KSI-301) inpatients with retinal vein occlusion)

• $Zai Lab(ZLAB.US)$ +12.7%(announced that the company's partner, $Karuna Therapeutics(KRTX.US)$, reported positive topline results from its Phase3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT, in adults with schizophrenia)

• $CinCor Pharma(CINC.US)$ +10.9%(announced the top line results and successful completion of its Phase 2 BrigHtn trial)

• $Myovant Sciences(MYOV.US)$ +10.4%(Myovant Sciences and $Pfizer(PFE.US)$ receive FDA approval of MYFEMBREE)

• $Stratasys(SSYS.US)$ +6.6%(to acquire Covestro's additive manufacturing materials business)

• $EQRx(EQRX.US)$ +4.9% (Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer)

• $Hutchmed (China)(HCM.US)$ +4.3%(Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary End point in Metastatic Colorectal Cancer)

• $Global Blood Therapeutics(GBT.US)$ +4.2% (Pfizer (PFE) confirms plans to acquireGlobal BloodTherapeuticsinTransaction valued at $68.50 per shareincash,fora total enterprise valueof~ $5.4billion)CGEN+2.7% (European Patent Office has granted Compugena new patent covering anti-PVRIG antibodies for use in cancer treatment)

• $Guardant Health(GH.US)$ +2.3% (Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC2022 World Conference on Lung Cancer)

• $CyberOptics(CYBE.US)$ +2.2%(Board of Directors has unanimously approved agreement for $Nordson(NDSN.US)$ to acquire Cyber Optics for $54.00 per share in cash)

• $LSB Industries(LXU.US)$ +1.8% (authorized an increaseinthe size of the previously announced$50 mln stock repurchase program implemented in May 2022)

• $Norwegian Cruise(NCLH.US)$ +1.7%(announced revisions toits SailSAFE health and safety protocols which further align the Company to the broader travel, leisure and hospitality industry worldwide)

• $Twitter (Delisted)(TWTR.US)$ +1.5% (Elon Musk tweets "If Twitter simply provides their method of sampling100 accounts and how they're confirmed to be real, the deal should proceed on original terms. However, if it turns out that their SEC filings are materially false, then it should not")

• $Tesla(TSLA.US)$ +1.4% (announces that its Board has approved previously announced intention to do a 3-for-l stock split; trading on split-adjusted basis to begin on August 25)

• $Reata Pharmaceuticals(RETA.US)$ -16%, $Palantir(PLTR.US)$ -15%, $uniQure NV(QURE.US)$ -13.9%, $BioNTech(BNTX.US)$ -3.5%, $Tyson Foods(TSN.US)$ -3%

• $Avalara(AVLR.US)$ -4% (Vista will acquire all outstanding shares of Avalara common stock for $93.50 per share in an all-cash transaction valued at $8.4 billion)

• $Via Renewables(VIA.US)$ -2.4% (files for $200 mln mixed securities shelf offering; also files for 20.8 mln share common stock offering by selling shareholders)

• $Grab Holdings(GRAB.US)$ -5.1% (downgraded to Neutral from Overweight at JP Morgan)

• $The AZEK(AZEK.US)$ -3.2% (downgraded to Neutral from Outperform at Wedbush)

• $Carvana(CVNA.US)$ -2.5% (downgraded to Underweight from Neutral at JP Morgan)